Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 3/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957000 | 0.87 | MEN1 (0.47) | PTGS2KMT2AMEN1MAOBSMN1; SMN2 | |
| SCHEMBL2965162 | 0.86 | PTGS2 (0.42) | PTGS2KMT2AMEN1MAOBSMN1; SMN2 | |
| SCHEMBL2967202 | 0.82 | MAOB (0.36) | PTGS2KMT2AMEN1MAOBRAB9A | |
| SCHEMBL30749724 | 0.78 | PTGS2 (0.51) | PTGS2KMT2AMEN1MAOBRAB9A | |
| SCHEMBL3754190 | 0.78 | PTGS2 (0.51) | PTGS2KMT2AMEN1MAOBRAB9A | |
| SCHEMBL14430960 | 0.73 | ALDH1A1 (0.49) | KMT2AMEN1MAOBMAOAKDM4E | |
| SCHEMBL2961235 | 0.73 | JUN (0.43) | MAOBRAB9ASMN1; SMN2MAOANPC1 | |
| SCHEMBL29661365 | 0.73 | MAPT (0.54) | KMT2AMEN1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL19198564 | 0.72 | NPC1 (0.47) | MAOBRAB9AMAOAKDM4EHSD17B1 | |
| SCHEMBL12104205 | 0.72 | TSHR (0.49) | MAOBRAB9ASMN1; SMN2MAOAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1445249-B1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-7772285-B2 | Benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| CN-101054345-B | Novel bensophenone derivatives or salts thereof | TOYAMA CHEMICAL CO LTD | 2010-06-02 | — | — | CN | disclosed |
| CN-1602291-B | Novel benzophenone derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2010-05-12 | — | — | CN | disclosed |
| CN-101402562-A | Novel benzophenone derivatives or salts thereof | TOYAMA CHEMICAL CO LTD (JP) | 2009-04-08 | — | — | CN | disclosed |
| CN-101054345-A | Novel bensophenone derivatives or salts thereof | TOYAMA CHEMICAL CO LTD (JP) | 2007-10-17 | — | — | CN | disclosed |
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SHUNICHI SHIOZAWA (JP) | 2005-05-26 | — | — | US | disclosed |
| CN-1602291-A | Novel benzophenone derivative or salt thereof | TOYAMA CHEMICAL CO LTD (JP) | 2005-03-30 | — | — | CN | disclosed |
| EP-1445249-A1 | NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113400-A1 | Inhibitors of transcription factor AP-1; autoimmune diseases; rheumatoid arthritis; high safety and excellent pharmacokinetics in vivo | SP1, AP1G1, JUN | PTGS2 1861/4885KMT2A 1394/4885MEN1 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.